2014
DOI: 10.1007/s10545-014-9724-5
|View full text |Cite
|
Sign up to set email alerts
|

Effective clearance of GL‐3 in a human iPSC‐derived cardiomyocyte model of Fabry disease

Abstract: Fabry disease, a rare X-linked α-galactosidase A deficiency, causes progressive lysosomal accumulation of globotriaosylceramide (GL-3) in a variety of cell types. As the disease progresses, renal failure, left ventricular hypertrophy, and strokes may occur. Enzyme replacement therapy (ERT), with recombinant α-galactosidase A, is currently available for use to reduce GL-3 deposits. However, although it improves cardiac function and decreases left ventricular mass, GL-3 clearance upon ERT has been demonstrated i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
36
1

Year Published

2015
2015
2023
2023

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 48 publications
(40 citation statements)
references
References 33 publications
3
36
1
Order By: Relevance
“…The presented data confirms and significantly expands on published work demonstrating that GCS inhibitors can reduce accumulated Gb3 in cultured cells derived from Fabry patients (33,45). In particular, Itier and colleagues have shown that GCS inhibitors can reduce accumulated Gb3, suggesting a role for clearance mechanisms other than α-GalA (45).…”
Section: Discussionsupporting
confidence: 90%
See 1 more Smart Citation
“…The presented data confirms and significantly expands on published work demonstrating that GCS inhibitors can reduce accumulated Gb3 in cultured cells derived from Fabry patients (33,45). In particular, Itier and colleagues have shown that GCS inhibitors can reduce accumulated Gb3, suggesting a role for clearance mechanisms other than α-GalA (45).…”
Section: Discussionsupporting
confidence: 90%
“…In particular, Itier and colleagues have shown that GCS inhibitors can reduce accumulated Gb3, suggesting a role for clearance mechanisms other than α-GalA (45). Alternative molecular clearance mechanisms, which may come into play in situations of high local intracellular Gb3 levels, include removal of the α-galactose by α-N-acetylgalactosaminidase (46,47) or conversion of Gb3 to lysoGb3 by acid ceramidase (6).…”
Section: Discussionmentioning
confidence: 99%
“…However, not all disease manifestations are corrected by ERT, prompting the identification of potential adjunctive therapies. For example, although the lipids that accumulate in endothelial cells of Fabry disease are efficiently cleared by rh α-Gal A, other cell types such as the glomerular podocytes and cardiomyocytes are reportedly less responsive to enzyme therapy (9,35,36) unless treatment starts early (10). The basis for the differential responses is in part related to the biodistribution of the administered enzyme (23) and the need for early intervention.…”
Section: Discussionmentioning
confidence: 99%
“…Several lines of evidence support the notion that SRT may be effective for Fabry disease. We recently reported that treatment of induced pluripotent stem cells (iPSC)-derived cardiomyocytes from a Fabry patient with Genz-682452 prevented the accumulation of GL-3 (36). We also previously demonstrated the feasibility of this concept in Fabry mice by using an earlier generation inhibitor of GCS, Genz-112638 (18).…”
Section: Discussionmentioning
confidence: 99%
“…Recently, Itier et al derived FD iPSC-CMs from two patient with GLA mutations to understand the role of GL-3 accumulation in the pathogenesis of FD-associated cardiomyopathy (25). The FD iPSC-CMs demonstrated progressive lysosomal accumulation of GL-3, increased lysosomal storage inclusions (zebra bodies), and disorganized contractile fibers.…”
Section: Carbohydrate Metabolismmentioning
confidence: 99%